ACASTI PHARMA INC (ACST) Stock Analyst Earnings Estimates
NASDAQ:ACST - Nasdaq - CA00430K8656 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 200K | -100.00% | 1.239M | 39.743M 3,107.67% | 72.783M 83.13% | 101.21M 39.06% | 118.83M 17.41% | ||||||
| EBITDA YoY % growth | -31.34M -136.17% | -22.12M 29.42% | -9.8M 55.70% | N/A -56.53% | N/A -18.19% | N/A 37.36% | -23.903M -110.48% | -26.838M -12.28% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.67M -119.35% | -24.44M 27.41% | -10.72M 56.14% | -17.238M -43.10% | -20.706M -18.97% | -16.61M 37.72% | -27.257M -139.79% | -26.423M 3.06% | -10.098M 61.78% | 8.564M 184.81% | 33.365M 289.60% | 47.922M 43.63% | |
| Operating Margin | N/A | N/A | -5,360.00% | N/A | N/A | N/A | N/A | -2,132.59% | -25.41% | 11.77% | 32.97% | 40.33% | |
| EPS YoY % growth | -9.12 7.63% | N/A -240.89% | N/A 80.95% | -0.86 85.53% | -2.69 -214.29% | -1.98 26.59% | -2.19 -11.02% | -1.78 19.11% | -0.16 90.82% | 0.61 474.72% | 1.56 155.09% | 2.15 37.91% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.64 -238.41% | -0.43 -42.68% | -0.33 -83.49% | -0.29 21.89% | -0.33 48.63% | -0.40 6.45% | -0.39 -16.67% |
| Revenue Q2Q % growth | 1.239M | ||||||
| EBITDA Q2Q % growth | -6.709M -225.70% | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.989M -237.63% | -6.193M -103.51% | -6.193M -89.79% | -5.505M -10.92% | -6.193M 11.39% | -7.569M -22.22% | -7.156M -15.56% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.37 -202.29% | -0.35 | -0.02 | -6.26% |
| Q4 2024 Q2Q % growth | -0.18 95.38% | -0.48 | 0.30 | 62.63% |
| Q3 2024 Q2Q % growth | -0.30 44.63% | -0.32 | 0.02 | 5.54% |
| Q2 2024 Q2Q % growth | -0.19 -72.73% | -0.11 | -0.08 | -69.34% |
| Q1 2024 Q2Q % growth | -22.40% | -0.12 | % | |
| Q4 2023 Q2Q % growth | -3.90 -390.20% | -0.86 | -3.04 | -355.18% |
| Q3 2023 Q2Q % growth | -0.54 20.35% | -0.94 | 0.40 | 42.72% |
| Q3 2022 Q2Q % growth | -0.68 | -0.49 | -0.19 | -38.48% |
| Q2 2021 Q2Q % growth | -0.10 96.18% | -0.65 | 0.55 | 84.07% |
| Q1 2021 Q2Q % growth | -0.55 54.00% | -0.57 | 0.02 | 3.36% |
| Q4 2020 Q2Q % growth | 1.94 210.00% | -0.90 | 2.83 | 315.69% |
| Q3 2020 Q2Q % growth | -0.01 97.68% | % | ||
| Q2 2020 Q2Q % growth | -2.72 45.16% | -0.73 | -1.99 | -270.37% |
| Q1 2020 Q2Q % growth | -1.20 34.78% | -1.14 | -0.06 | -5.04% |
| Q4 2019 Q2Q % growth | -1.76 | -1.22 | -0.54 | -43.79% |
| Q3 2019 Q2Q % growth | -0.56 | -1.14 | 0.58 | 50.98% |
| Q2 2019 Q2Q % growth | -4.96 | -2.28 | -2.68 | -117.09% |
| Q1 2019 Q2Q % growth | -1.84 | -2.20 | 0.36 | 16.49% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -50.72% | 0% | -42.38% |
| Revenue | N/A | N/A | N/A | N/A |